corticosteroids improve outcomes in Pneumocystis jiroveci pneumonia 15 and bacterial meningitis. 16 The first randomized trial of corticosteroids in CAP was published in 1956, 17 and since then, there have been a number of other randomized trials.
Introduction Community-acquired pneumonia (CAP) is the leading cause of infectious death in developed countries, 1 and lower respiratory infections are the second leading cause of life-years lost globally. 2 CAP is associated with billions of Euros in health care costs annually.
3,4 Among hospitalized patients with CAP, mortality rates have remained high 5 despite advances in antibiotic therapy 6 and supportive care.
7,8
CAP occurs when bacterial pathogens overcome the innate immune defences of the lower respiratory tract. 9 There is a subsequent intense and prolonged inflammatory response.
10 Although the local and systemic inflammatory responses may be necessary to clear the infection, they can also cause harm. The degree and duration of the inflammatory response are inversely associated with poor outcomes.
10 Inflammation can worsen alveolar gas exchange, and in severe cases, leads to acute respiratory distress syndrome (ARDS).
11,12
The most common cause of ARDS is pneumonia.
13
Severe inflammation also contributes to septic shock and end-organ dysfunction.
11,14
There has been considerable interest in immunomodulating agents, including corticosteroids, in the treatment of infections. For example, C-reactive protein (CRP) greater than 150 mg/l (950 mmol/l) to methylprednisolone 0.5 mg/ kg or placebo every 12 hours. 29 The primary outcome was treatment failure, which was defined as a composite of septic shock, need for invasive mechanical ventilation, and death within 5 days or a ≥50% increase in radiographic pulmonary infiltrates or persistence of severe respiratory failure between days 3 and 5.
This trial also showed an apparent benefit in the primary outcome: 31% of patients had a treatment failure with placebo compared with 13% with methylprednisolone (P = 0.02). The results were driven by treatment failures occurring after 3 days (25% vs 3%, P = 0.001), because of a decrease in radiographic progression of disease (15% vs 2%, P = 0.007). Persistent respiratory failure, the need for mechanical ventilation, and septic shock were all less frequent in the methylprednisolone group, though none of these outcomes in themselves reached statistical significance.
The small sample size and very large effect driven by an outcome that is not important to patients limits inferences from this latest study. The suggestion of positive effects of corticosteroids is, however, consistent with all previous studies.
Should corticosteroids be restricted to patients with severe community-acquired pneumonia? The mortality benefit of corticosteroids remains uncertain, and if it does exist, it may be restricted to patients with severe CAP. 35, 36 This suggests that the most compelling indication for corticosteroid use may be in patients with more severe CAP.
Regardless of whether there is a mortality benefit from the use of corticosteroids in CAP-and whether it is restricted to the more severe patients-results convincingly demonstrate a reduction in time to symptom resolution/clinical stability and reduced length of stay in patients across the broad range of patients with CAP. An exploratory analysis in the largest trial failed to identify a difference in effect in those with higher versus lower disease severity. 28 A reduction in hospital stay by 1 day would lead to considerable cost savings given that the median cost of hospitalization for CAP is €1200 to €6900 in Europe.
43,44 The 1-day reduction is very similar to that demonstrated in patients with exacerbations of chronic obstructive pulmonary disease 45 and corticosteroid use is well accepted and used broadly for this condition.
46
Adverse effects of corticosteroids Corticosteroids have been used for decades and their adverse effects are well known. Short-term use is associated with hyperglycemia, which is typically transient. 28, 45 Neuropsychiatric side effects, which range from insomnia and irritability to mania, psychosis, and delirium, also occur.
47 Gastrointestinal bleeding and secondary infections, other commonly cited adverse effects, do not appear to be increased with short-term use.
45
to a 10-day hydrocortisone intravenous infusion or placebo. The trial was stopped early for benefit when eight (38%) of 23 patients died in the placebo group compared to none in the hydrocortisone group (P = 0.001). The Italian trial almost certainly overestimated the effect size: the mortality rate was higher than expected in the placebo group, and the trial was stopped early for benefit without predefined stopping criteria. 30 Meta-analyses prior to the most recent trials Meta--analyses of corticosteroids for CAP have reported varying findings, some suggesting a mortality benefit in those with severe CAP, 35, 36 with low--dose corticosteroids, 37 or with prolonged administration. 35 No studies found a significant mortality benefit across all patients with CAP.
38-41
A Cochrane review including patients with diverse types of pneumonia (eg, including Mycoplasma pneumoniae pneumonia) found low quality evidence that corticosteroids reduced the time to symptom resolution and decreased the rate of relapsed disease. 38 However, most of the clinical trials included in previous meta-analyses were small, enrolling less than 100 patients (TABLE 1) . Two recent trials have further informed the discussion. 28, 29 Recent randomized trials Blum et al. 28 randomized 785 patients hospitalized with CAP of varying severity to 50 mg of prednisone or placebo for 7 days. The primary outcome was time to clinical stability, defined as 24 hours after all vital signs normalized, including arterial oxygenation and mental status.
The trial showed a convincing impact on the primary endpoint, reducing the median time to clinical stability by over 1 day from 4.4 (interquartile range, 4.0-5.0) days in the placebo group to 3.0 (interquartile range, 2.5-3.4) days in the prednisone group (hazard ratio [HR], 1.33; 95% confidence interval [CI], 1.15-1.50). There was a corresponding decrease in a median length of hospital stay by 1 day (7 vs 6 days, P = 0.012) and a suggestion of a possible reduction in pneumonia--associated complications (6% vs 3%, P = 0.056).
In-hospital hyperglycemia requiring new insulin therapy was more common in the intervention arm (19% vs 11%, P = 0.001), but there was no convincing difference in other adverse events including new insulin dependence at day 30 (1.3% in the prednisone group vs 0.3% in the placebo group, P = 0.12) or in intensive care admission, readmission, or mortality.
The findings of the trial are credible: it was well designed and executed, with low probability of bias. The finding of more rapid symptom resolution 17,20,22,24 and shorter length of hospital stay 20,21,25,27 is consistent with previous trials. The second recent trial randomized 120 patients hospitalized with severe CAP 42 and a serum Patients with higher risks of severe hyperglycemia (eg, those with fragile diabetes) or neuropsychiatric side effects (eg, patients with a history of corticosteroid-induced neuropsychiatric complications) might prefer to avoid the risk of these side effects. Given the relatively infrequent and transient nature of the adverse effects, it is likely that most informed patients would choose an intervention that reduces their stay in hospital by a day.
Dosing The randomized trials have tested a variety of corticosteroid agents, doses, and durations, leaving the optimal dose and duration uncertain. Most trials, however, used 3 to 7 days of moderate dose corticosteroids (approximately 0.5-1 mg/kg of prednisone-equivalent per 24 hours).
Conclusions Adjunctive corticosteroids for treatment of CAP reduce the duration of symptoms and hospitalization by approximately 1 day. There may also be a mortality benefit, which may be restricted to those with more severe disease, although this is less certain. If there is any impact on mortality, it is a reduction. These results suggest the possibility that routine use of corticosteroids in patients with CAP should become a standard of care. 
